中国中西医结合杂志
中國中西醫結閤雜誌
중국중서의결합잡지
CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE
2010年
4期
380-382
,共3页
冠心痛%阿司匹林抵抗%通心络胶囊%血小板聚集
冠心痛%阿司匹林牴抗%通心絡膠囊%血小闆聚集
관심통%아사필림저항%통심락효낭%혈소판취집
coronary heart disease%aspirin resistance%Tongxinluo Capsule%platelet aggregation
目的 探讨通心络胶囊对阿司匹林抵抗(aspirin resistance,AR)的冠心痛患者血小板聚集的影响.方法 选择正规服用阿司匹林(100 mg/d)超过1个月的冠心病患者330例,分别用胶原(collagen,COL)和二磷酸腺苷(adenosine diphosphate,ADP)作为诱导剂测定其静脉血中血小板聚集值,根据结果筛选出AR患者,随机分为3组.联合治疗组:服用通心络胶囊,每次3粒,1天3次,并加服阿司匹林,100 mg/d;通心络组:服用通心络胶囊,每次3粒,1天3次;阿司匹林组:继续服用阿司匹林,100 mg/d.疗程均为1个月.检测治疗前及治疗1个月后的血小板聚集值.结果 330例患者中89例存在阿司匹林抵抗,占26.97%.联合治疗组与通心络组服药1个月后血小板聚集值较治疗前均明显下降,差异有统计学意义(P<0.05),阿司匹林组较治疗前无明显改变.治疗后联合治疗组、通心络组的血小板聚集值与阿司匹林组比较均有统计学意义(P<0.05).结论 通心络胶囊对ADP和COL诱导血小板聚集值有一定的降低作用.
目的 探討通心絡膠囊對阿司匹林牴抗(aspirin resistance,AR)的冠心痛患者血小闆聚集的影響.方法 選擇正規服用阿司匹林(100 mg/d)超過1箇月的冠心病患者330例,分彆用膠原(collagen,COL)和二燐痠腺苷(adenosine diphosphate,ADP)作為誘導劑測定其靜脈血中血小闆聚集值,根據結果篩選齣AR患者,隨機分為3組.聯閤治療組:服用通心絡膠囊,每次3粒,1天3次,併加服阿司匹林,100 mg/d;通心絡組:服用通心絡膠囊,每次3粒,1天3次;阿司匹林組:繼續服用阿司匹林,100 mg/d.療程均為1箇月.檢測治療前及治療1箇月後的血小闆聚集值.結果 330例患者中89例存在阿司匹林牴抗,佔26.97%.聯閤治療組與通心絡組服藥1箇月後血小闆聚集值較治療前均明顯下降,差異有統計學意義(P<0.05),阿司匹林組較治療前無明顯改變.治療後聯閤治療組、通心絡組的血小闆聚集值與阿司匹林組比較均有統計學意義(P<0.05).結論 通心絡膠囊對ADP和COL誘導血小闆聚集值有一定的降低作用.
목적 탐토통심락효낭대아사필림저항(aspirin resistance,AR)적관심통환자혈소판취집적영향.방법 선택정규복용아사필림(100 mg/d)초과1개월적관심병환자330례,분별용효원(collagen,COL)화이린산선감(adenosine diphosphate,ADP)작위유도제측정기정맥혈중혈소판취집치,근거결과사선출AR환자,수궤분위3조.연합치료조:복용통심락효낭,매차3립,1천3차,병가복아사필림,100 mg/d;통심락조:복용통심락효낭,매차3립,1천3차;아사필림조:계속복용아사필림,100 mg/d.료정균위1개월.검측치료전급치료1개월후적혈소판취집치.결과 330례환자중89례존재아사필림저항,점26.97%.연합치료조여통심락조복약1개월후혈소판취집치교치료전균명현하강,차이유통계학의의(P<0.05),아사필림조교치료전무명현개변.치료후연합치료조、통심락조적혈소판취집치여아사필림조비교균유통계학의의(P<0.05).결론 통심락효낭대ADP화COL유도혈소판취집치유일정적강저작용.
Objective To investigate the effect of Tongxinluo Capsule(TXLC)on platelet aggregation in patients of coronary heart disease(CHD)with aspirin resistance(AR).Methods Patients with AR were screened out from 330 CHD patients,who had regularly taken aspirin(100 mg/d)for more than one month,by testing platelet aggregation level after adenosine diphosphate(ADP)and collagen(COL)induction.They were randomly assigned to three groups: the combined treatment group treated by TXLC + aspirin,the TXL group treated by TXLC alone and the AS group treated by aspirin alone,at the dose of TXLC 3 capsules thrice a day,and that of aspirin 100 mg/d.The therapeutic course for all was one month.Patients' platelet aggregation was measured before and after 1-month treatment.Results Eighty-nine patients with AR were screened out from the 330 CHD patients,the occurrence rate being 26.97%.Platelet aggregation was significantly decreased after 1-month treatment in the combined treatment group and the TXL groups(P<0.05),but changed insignificantly in the AS group,the difference between the former two and the latter group was statistically significant(P<0.05).Conclusion TXLC has definite effect in reducing the ADP + COL induced platelet aggregation.